DOCSLIB.ORG

USP Veterinary Pharmaceutical Information Monographs – Antibiotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
USP Veterinary Pharmaceutical Information Monographs – Antibiotics volume 26 supplement 2 october 2003 USP Veterinary Pharmaceutical Information Monographs – Antibiotics USP VETERINARY PHARMACEUTICAL INFORMATION MONOGRAPHS – ANTIBIOTICS CONTENTS v Introduction 1 Aminoglycosides (Veterinary—Systemic) 33 Aminopenicillins (Veterinary—Intramammary-Local) 36 Aminopenicillins (Veterinary—Systemic) 46 Amoxicillin and Clavulanate (Veterinary—Systemic) 51 Cephalosporins (Veterinary—Systemic) 71 Cephapirin (Veterinary—Intramammary-Local) 74 Chloramphenicol (Veterinary—Systemic) 79 Erythromycin (Veterinary—Intramammary-Local) 81 Florfenicol (Veterinary—Systemic) 87 Fluoroquinolones (Veterinary—Systemic) 109 Lincosamides (Veterinary—Systemic) 119 Macrolides (Veterinary—Systemic) 144 Metronidazole (Veterinary—Systemic) 149 Penicillin G (Veterinary—Intramammary-Local) 151 Penicillin G (Veterinary—Systemic) 161 Pirlimycin (Veterinary—Intramammary-Local) 164 Potentiated Sulfonamides (Veterinary—Systemic) 185 Pyrimethamine (Veterinary—Systemic) 191 Rifampin (Veterinary—Systemic) 202 Spectinomycin (Veterinary—Systemic) 207 Sulfonamides (Veterinary—Systemic) 225 Tetracyclines (Veterinary—Systemic) 253 Indications Index 257 Dosing Index 262 Veterinary Brand and Generic Name Index 269 Human Brand and Generic Name Index Introduction v Introduction WHAT’S DIFFERENT ABOUT A USP DRUG INFORMATION included where it may be helpful. Each draft chapter or monograph is MONOGRAPH then put through a review process that includes USP Veterinary The Veterinary Medicine Expert Committee on Drug Information Medicine Committee members, regulatory representatives, pharma- gratefully acknowledges the financial support of its parent organiza- ceutical manufacturers, ad hoc specialists, and public review. At tion, the United States Pharmacopeia, to publish these monographs. It present, USP monographs are the only drug information source in also is appreciative to the Food Animal Residue Avoidance Databank veterinary medicine undergoing such extensive expert review, (FARAD) for supplying slaughter and milk withdrawal information a process through which the credibility of the information is where extra-label drug use in food animals is noted. This information is maintained. provided in cooperation with MICROMEDEX, a Thomson Healthcare USP drug information is a work-in-progress. The information is in Company. constant revision and is a continuous collection of the current judgments of experts in the use of medications. The following chapters have been developed over 7 years, with information added and revised, USP history, organizational structure, and publications as necessary. In pursuit of its mission to promote public health, the United States Pharmacopeia (USP) develops authoritative information about the appropriate use of medicines, including those used in animals. This Unique features non-government, not-for-profit organization draws on a long-standing This special issue of the Journal of Veterinary Pharmacology and dedication to public involvement in the establishment of scientific Therapeutics contains a series of drug information monographs on standards. USP achieves its goals through the contributions of antimicrobials used in veterinary medicine. What makes this volunteers representing health care professions, as well as science, information different from other sources of veterinary drug informa- academia, the U.S. government, the pharmaceutical industry, and tion? A succinct listing would include: consumer organizations. • The incorporation of extra-label and label indications and dosages USP was established in 1820 with the primary goal of setting standards for all domestic species. See the section below, ‘‘Finding the specific for the identity, strength, and quality of medicinal compounds and this drug information you need; Label and extra-label uses,’’ for details remains at the core of the organization. Currently, USP provides on how this information is differentiated. standards for more than 3,800 prescription and non-prescription • The inclusion of slaughter and milk withdrawals when extra-label drugs, nutritional and dietary supplements, veterinary drugs, and drug use in food animals is considered an acceptable option for health care products. These standards are published in the United therapy. Withdrawal times have been provided by FARAD for the States Pharmacopeia (USP) and the National Formulary (NF), which are specified conditions noted. officially recognized in the Federal Food, Drug, and Cosmetic Act (21 • The inclusion of information about both U.S. and Canadian U.S.C. § 321 et seq.). USP also produces Reference Standards, which veterinary drug products. are an integral part of USP’s standards program. • The grouping of indications into three categories. The ‘‘Accepted’’ The development of USP information on the best use of medications was category indicates that clear evidence exists to support use of the begun in 1970, growing out of the public process of developing quality drug for a particular purpose. ‘‘Acceptance not established’’ standards. USP information advisory panels were created to assure (potentially useful) indicates that use of the drug for an indication that the information under development is evidence-based, consensus- may be worthy of consideration if superior therapies do not exist, established, practical, and clinically relevant. This work was expanded but the evidence is either scant or subject to concern based on into a separate public health program and in 1980, the first USP DIÒ experimental design. If a use is viewed as ineffective or has been was published. Today, in association with MICROMEDEX, USP replaced by clearly superior therapies, the indication is deemed continues to provide oversight and approval of drug information ‘‘Unaccepted.’’ These categorizations are applied to label and extra- content in the USP DIÒ database, which covers nearly all medicines in label uses. the U.S. and Canada. • The use of tables of scientific evidence to address controversial issues during the review process, particularly relative to extra-label drug use. The veterinary drug information monograph creation process • Review of the information by a Food and Drug Administration (FDA) Very soon after the USP DIÒ was first published, an advisory panel on liaison to the committee. Although comments made by the FDA are veterinary medicine was created. Since 1982, veterinary pharmacol- taken quite seriously, those opinions are nonbinding on the USP. ogists, veterinary pharmacists, and other specialists have contributed The information contained in these monographs should not be their time and expertise in creating and revising drug information considered an endorsement or ‘‘acceptance’’ by the FDA as to a through USP’s unique process. This drug information is developed by given use or dosage. exhaustive compilation of approved product label information and also • The review of each monograph by the USP Veterinary Medicine collection and analysis of publicly available data on each drug from Committee. This committee consists of 10 to 15 volunteers research studies and clinical reports. Careful attention is paid to recognized as experts in pharmacology, internal medicine, or species differentiating species-specific information. With the agreement of discipline(s). MICROMEDEX, information from the human USP DIÒ database is Ó 2003 Thomson MICROMEDEX All rights reserved vi Introduction Finding the specific drug information you need ACKNOWLEDGEMENTS The following individuals are recognized for their contributions and Label and extra-label uses support towards the production of this body of work: The Indications section of each drug monograph is designed to provide information about indications in drug product labeling in the U.S. and USP Staff Canada. Extra-label indications for which clinical and research data Roger Williams, MD (CEO and Executive Vice President, USP) have been evaluated are also included. Indications found in product Ian DeVeau, PhD (Senior Scientist, Veterinary Drugs, Information and labeling are listed first. Brackets around an indication signify that it is Standards Development, USP) not found in any product labeling in the U.S. at the time of last major Amy S. Neal, DVM (USP consultant, writer and editor) revision. Some indications are followed by a superscript 1, meaning Jerome A. Halperin, BS, MPH, MS (former CEO and Executive Vice they are not included in Canadian product labeling. President, USP) Keith Johnson (former Director, Drug Information Division, USP) Examples of bracket and superscript 1 placement in the monographs: David Nash, DVM (former Director, Veterinary Medicine, Information [Pneumonia, bacterial (treatment)] An extra-label use in the U.S. and Standards Development, USP) An indication is included in E. Kathryn Meyer, VMD (former Drug Information Specialist and Canadian product labeling. Coordinator, Veterinary Practitioners’ Reporting Program, Pneumonia, bacterial (treatment)1 An indication found in U.S. USP) product labeling but not in Canadian product labeling. 2000 to 2005 Veterinary Medicine Committee [Pneumonia, bacterial (treatment)]1 An extra-label use in both the Cory Langston, DVM, PhD, DACVCP, Chair U.S. and Canada. Michael D. Apley, DVM, PhD, BS, DACVCP Dawn M. Boothe, BS, MS, DVM, PhD, DACVCP, DACVIM Species and dosage forms Terrence P. Clark, DVM, PhD, DACVCP Within each category of the Indications section the information is arranged Gigi F. Davidson, BS, RPh, DICVP in a hierarchy as follows: indication, followed by the species to which Patricia Dowling, DVM,
Load more

Recommended publications
  • Genomic and Evolutionary Insights
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Apollo GBE Preterm Infant-Associated Clostridium tertium, Clostridium cadaveris,andClostridium paraputrificum Strains: Genomic and Evolutionary Insights Raymond Kiu1,2, Shabhonam Caim1, Cristina Alcon-Giner1, Gusztav Belteki3,PaulClarke4, Derek Pickard5, Gordon Dougan5,andLindsayJ.Hall1,* 1The Gut Health and Food Safety Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom 2Norwich Medical School, Norwich Research Park, University of East Anglia, Norwich, United Kingdom 3Neonatal Intensive Care Unit, The Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, United Kingdom 4Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom 5Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom *Corresponding author: E-mail: [email protected]. Accepted: September 28, 2017 Data deposition: This project has been deposited at European Nucleotide Archive (EMBL-EBI) under the accession PRJEB22142. Bacterial strain deposition: Newly sequenced strains are deposited at National Collection of Type Cultures (NCTC; a culture depository of Public Health England). Abstract Clostridium species (particularly Clostridium difficile, Clostridium botulinum, Clostridium tetani and Clostridium perfringens)are associated with a range of human and animal diseases. Several other species including Clostridium tertium, Clostridium cadaveris, and Clostridium paraputrificum have also been linked with sporadic human infections, however there is very limited, or in some cases, no genomic information publicly available. Thus, we isolated one C. tertium strain, one C. cadaveris strain and three C. paraputrificum strains from preterm infants residing within neonatal intensive care units and performed Whole Genome Sequencing (WGS) using Illumina HiSeq. In this report, we announce the open availability of the draft genomes: C.
    [Show full text]
  • Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks
    processes Review Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks Manuel Conde-Cid 1, Avelino Núñez-Delgado 2 , María José Fernández-Sanjurjo 2 , Esperanza Álvarez-Rodríguez 2, David Fernández-Calviño 1,* and Manuel Arias-Estévez 1 1 Soil Science and Agricultural Chemistry, Faculty Sciences, University Vigo, 32004 Ourense, Spain; [email protected] (M.C.-C.); [email protected] (M.A.-E.) 2 Department Soil Science and Agricultural Chemistry, Engineering Polytechnic School, University Santiago de Compostela, 27002 Lugo, Spain; [email protected] (A.N.-D.); [email protected] (M.J.F.-S.); [email protected] (E.Á.-R.) * Correspondence: [email protected] Received: 30 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Veterinary antibiotics are widely used worldwide to treat and prevent infectious diseases, as well as (in countries where allowed) to promote growth and improve feeding efficiency of food-producing animals in livestock activities. Among the different antibiotic classes, tetracyclines and sulfonamides are two of the most used for veterinary proposals. Due to the fact that these compounds are poorly absorbed in the gut of animals, a significant proportion (up to ~90%) of them are excreted unchanged, thus reaching the environment mainly through the application of manures and slurries as fertilizers in agricultural fields. Once in the soil, antibiotics are subjected to a series of physicochemical and biological processes, which depend both on the antibiotic nature and soil characteristics. Adsorption/desorption to soil particles and degradation are the main processes that will affect the persistence, bioavailability, and environmental fate of these pollutants, thus determining their potential impacts and risks on human and ecological health.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • WO 2018/064165 A2 (.Pdf)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/064165 A2 05 April 2018 (05.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 35/74 (20 15.0 1) C12N 1/21 (2006 .01) — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/053717 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 September 2017 (27.09.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/400,372 27 September 2016 (27.09.2016) US 62/508,885 19 May 2017 (19.05.2017) US 62/557,566 12 September 2017 (12.09.2017) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSI¬ TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, TX 78701 (US). (72) Inventors: WARGO, Jennifer; 1814 Bissonnet St., Hous ton, TX 77005 (US). GOPALAKRISHNAN, Vanch- eswaran; 7900 Cambridge, Apt. 10-lb, Houston, TX 77054 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Product Summary Resumen De Productos
    sommaire du produit product summary resumen de productos www.dutchfarmint.com P R O D U C T S U M M A R Y VETERINARY PHARMACEUTICALS & NUTRACEUTICALS DETERGENTS & DISINFECTANTS PREMIXTURES & ADDITIVES COMPOUND & COMPLEMENTARY FEEDS Dutch Farm International B.V. Nieuw Walden 112 – 1394 PE Nederhorst den Berg - Holland P.O. Box 10 – 1394 ZG Nederhorst den Berg - Holland T: +31 294 25 75 25 - M : +31 6 53 86 88 53 E: [email protected] For the latest news about our company and our product range: visit our website! www.dutchfarmint.com – www.dufamix.com – www.dufafeed.com – www.dufasept.com "Dutch Farm" is a registered trademark Pharmaceutical manufacturer authorisation no. 2418-FIGL Feed business authorisation no. αNL207231 March 2019 Pour-ons Intramammary injectors Dufamec 0.5% Pour-On 39 Cloxa-Ben Dry Cow 92 Kanapen-P 93 Injectables Dufamec 1% 40 ANTI-INFLAMMATORIES VITAMINS & MINERALS Dufamec-N 5/250 41 Dufaquone 5% 42 Dexamethason 0.2% inj 94 Water soluble powders Dufaprofen 10% inj 95 Dufadigest Powder 4 Powders for injection Phenylbutazon 20% inj 96 Vitacon Extra 5 Dufanazen 43 ANAESTHETICS Tablets ANTIBIOTICS Vitamineral-Dog Tablets 6 Ketamin 10% inj 97 Water soluble powders Xylazin 2% inj 99 Oral liquids Colistine 4800 45 Dufa-Calcio Gel 7 Doxycycline 20% 46 ANTIPYRETICS Dufa-Start 8 Dufadox-G 100/100 wsp 47 Dufamin Oral 9 Dufamox 50% 49 Dufapirin C+K3 wsp 101 Dufaminovit Oral 10 Dufamox-C 200/2mln 51 Dufavit AD3E 100/20/20 11 Dufampicillin 50% 53 HORMONES Dufavit E 15% + Sel Oral 12 Dufaphos-T 54 Electrolysol Oral 13 Fenosvit-C
    [Show full text]
  • Clinical Presentations and Antimicrobial Susceptibilities of Corynebacterium Cystitidis Associated with Renal Disease in Four Beef Cattle
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Faculty Publications and Other Works -- Large Veterinary Medicine -- Faculty Publications and Animal Clinical Sciences Other Works 8-24-2020 Clinical presentations and antimicrobial susceptibilities of Corynebacterium cystitidis associated with renal disease in four beef cattle Joseph Smith ISU, UTK, [email protected] Adam C. Krull ISU Jennifer A. Schleining ISU, TAMU Rachel J. Derscheid ISU Amanda J. Kreuder ISU, [email protected] Follow this and additional works at: https://trace.tennessee.edu/utk_largpubs Part of the Bacteria Commons, Large or Food Animal and Equine Medicine Commons, and the Veterinary Microbiology and Immunobiology Commons Recommended Citation Smith, JS, Krull, AC, Schleining, JA, Derscheid, RJ, Kreuder, AJ. Clinical presentations and antimicrobial susceptibilities of Corynebacterium cystitidis associated with renal disease in four beef cattle. J Vet Intern Med. 2020; 34: 2169– 2174. https://doi.org/10.1111/jvim.15844 This Article is brought to you for free and open access by the Veterinary Medicine -- Faculty Publications and Other Works at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Faculty Publications and Other Works -- Large Animal Clinical Sciences by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Received: 22 April 2020 Accepted: 26 June 2020 DOI: 10.1111/jvim.15844 CASE REPORT Clinical presentations
    [Show full text]
  • ORGANIC CHEMICAL TOXICOLOGY of FISHES This Is Volume 33 in The
    ORGANIC CHEMICAL TOXICOLOGY OF FISHES This is Volume 33 in the FISH PHYSIOLOGY series Edited by Anthony P. Farrell and Colin J. Brauner Honorary Editors: William S. Hoar and David J. Randall A complete list of books in this series appears at the end of the volume ORGANIC CHEMICAL TOXICOLOGY OF FISHES Edited by KEITH B. TIERNEY Department of Biological Sciences University of Alberta Edmonton, Alberta Canada ANTHONY P. FARRELL Department of Zoology, and Faculty of Land and Food Systems The University of British Columbia Vancouver, British Columbia Canada COLIN J. BRAUNER Department of Zoology The University of British Columbia Vancouver, British Columbia Canada AMSTERDAM BOSTON HEIDELBERG LONDON NEW YORK OXFORD PARIS SAN DIEGO SAN FRANCISCO SINGAPORE SYDNEY TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 225 Wyman Street, Waltham, MA 02451, USA 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA Copyright r 2014 Elsevier Inc. All rights reserved The cover illustrates the diversity of effects an example synthetic organic water pollutant can have on fish. The chemical shown is 2,4-D, an herbicide that can be found in streams near urbanization and agriculture. The fish shown is one that can live in such streams: rainbow trout (Oncorhynchus mykiss). The effect shown on the left is the ability of 2,4-D (yellow line) to stimulate olfactory sensory neurons vs. control (black line) (measured as an electro- olfactogram; EOG). The effect shown on the right is the ability of 2,4-D to induce the expression of an egg yolk precursor protein (vitellogenin) in male fish.
    [Show full text]
  • Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites
    DMD Fast Forward. Published on December 31, 2018 as DOI: 10.1124/dmd.118.084772 This article has not been copyedited and formatted. The final version may differ from this version. DMD #84772 Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites Yukuang Guo1,5, Camila Manoel Crnkovic1, Kyoung-Jae Won2, Xiaotong Yang4, John Richard Lee3, Jimmy Orjala1,5, Hyunwoo Lee1,5, and Hyunyoung Jeong2,4,5 1, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago Downloaded from 2, Department of Pharmacy Practice, University of Illinois at Chicago 3, Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine 4, Department of Biopharmaceutical Sciences, University of Illinois at Chicago dmd.aspetjournals.org 5, Center for Biomolecular Sciences at ASPET Journals on September 26, 2021 1 DMD Fast Forward. Published on December 31, 2018 as DOI: 10.1124/dmd.118.084772 This article has not been copyedited and formatted. The final version may differ from this version. DMD #84772 Running title: Tacrolimus metabolism by gut bacteria Correspondence and requests for materials should be addressed to J.O. (for tacrolimus metabolite M1), H.L. (for bacteria), and H.J. (for the rest). Jimmy Orjala, [email protected] Hyunwoo Lee, [email protected] Hyunyoung Jeong, [email protected] College of Pharmacy, University of Illinois at Chicago Downloaded from 900 South Ashland Ave, Chicago, IL 60607 # text pages: 26 dmd.aspetjournals.org # table: 3 # figure: 6 # references: 32 at ASPET
    [Show full text]
  • 55 - Fao Fnp 41/16
    PIRLIMYCIN First draft prepared by Lynn G. Friedlander, Rockville, MD, United States Gérard Moulin, Fougères, France IDENTITY Chemical Names: (2S-cis)-Methyl 7-chloro-6,7,8-trideoxy-6-[[(4-ethyl-2- piperidinyl)carbonyl]amino]-1-thio-L-threo-alpha-D-galactooctopyranoside monohydrochloride, hydrate Synonyms: Pirlimycin hydrochloride PIRSUE® Sterile Solution PNU-57930E Structural formula: Molecular formula: C17H31O5N2ClS • HCl • xH2O Molecular weight: 447.42 (without the water of hydration) OTHER INFORMATION ON IDENTITY AND PROPERTIES Pure active ingredient: Pirlimycin Appearance: White crystalline powder Melting point: 210.5 – 212.5°C with decomposition Solubility (g/L) of pH dependent aqueous: 70 at pH 4.5 Pirlimycin: 3 at pH 13 Protic organic solvents: ≥ 100 Other organic solvents: ≤ 10 Optical rotation: +170° to +190° UVmax: >220 nm - 55 - FAO FNP 41/16 RESIDUES IN FOOD AND THEIR EVALUATION Conditions of use General Pirlimycin hydrochloride is a lincosamide antibiotic with activity against the Gram-positive organisms. Pirlimycin has been shown to be efficacious for the treatment of mastitis in lactating dairy cattle caused by sensitive organisms such as Staphylococcus aureus, Streptococcus agalactiae, S. uberis and S. dysgalactiae. The general mechanism of action of the lincosamides (lincomycin, clindamycin and pirlimycin) is inhibition of protein synthesis in the bacterial cell, specifically by binding to the 50s ribosomal subunit and inhibiting the peptidyl transferase, with subsequent interference with protein synthesis. Dosage The optimum dose rate for pirlimycin has been established as 50 mg of free base equivalents per quarter administered twice at a 24-hour interval by intramammary infusion of a sterile aqueous solution formulation. For extended therapy, daily treatment may be repeated for up to 8 consecutive days.
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption National
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2020 Publication : 22 June 2021 1 SUMMARY This annual BelVet-SAC report is now published for the 12th time and describes the antimicrobial use (AMU) in animals in Belgium in 2020 and the evolution since 2011. For the third year this report combines sales data (collected at the level of the wholesalers-distributors and the compound feed producers) and usage data (collected at farm level). This allows to dig deeper into AMU at species and farm level in Belgium. With a consumption of 87,6 mg antibacterial compounds/kg biomass an increase of +0.2% is seen in 2020 in comparison to 2019. The increase seen in 2020 is spread over both pharmaceuticals (+0.2%) and antibacterial premixes (+4.0%). This unfortunately marks the end of a successful reduction in antibacterial product sales that was seen over the last 6 years resulting in a cumulative reduction of -40,2% since 2011. The gap seen in the coverage of the sales data with the Sanitel-Med collected usage data increased substantially compared to 2019, meaning continuous efforts need to be taken to ensure completeness of the collected usage data. When looking at the evolution in the number of treatment days (BD100) at the species level, as calculated from the SANITEL- MED use data, use increased in poultry (+5,0%) and veal calves (+1,9%), while it decreased in pigs (-3,1%). However, the numerator data for this indicator remain to be updated for 2020, potentially influencing the reliability of the result.
    [Show full text]
  • Swedres-Svarm 2019
    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
    [Show full text]
  • Biosynthesis of Natural Products Containing Β-Amino Acids
    Natural Product Reports Biosynthesis of natural products containing β -amino acids Journal: Natural Product Reports Manuscript ID: NP-REV-01-2014-000007.R1 Article Type: Review Article Date Submitted by the Author: 21-Apr-2014 Complete List of Authors: Kudo, Fumitaka; Tokyo Institute Of Technology, Department of Chemistry Miyanaga, Akimasa; Tokyo Institute Of Technology, Department of Chemistry Eguchi, T; Tokyo Institute Of Technology, Department of Chemistry and Materials Science Page 1 of 20 Natural Product Reports NPR RSC Publishing REVIEW Biosynthesis of natural products containing βββ- amino acids Cite this: DOI: 10.1039/x0xx00000x Fumitaka Kudo, a Akimasa Miyanaga, a and Tadashi Eguchi *b Received 00th January 2014, We focus here on β-amino acids as components of complex natural products because the presence of β-amino acids Accepted 00th January 2014 produces structural diversity in natural products and provides characteristic architectures beyond that of ordinary DOI: 10.1039/x0xx00000x α-L-amino acids, thus generating significant and unique biological functions in nature. In this review, we first survey the known bioactive β-amino acid-containing natural products including nonribosomal peptides, www.rsc.org/ macrolactam polyketides, and nucleoside-β-amino acid hybrids. Next, the biosynthetic enzymes that form β-amino acids from α-amino acids and de novo synthesis of β-amino acids are summarized. Then, the mechanisms of β- amino acid incorporation into natural products are reviewed. Because it is anticipated that the rational swapping of the β-amino acid moieties with various side chains and stereochemistries by biosynthetic engineering should lead to the creation of novel architectures and bioactive compounds, the accumulation of knowledge regarding β- amino acid-containing natural product biosynthetic machinery could have a significant impact in this field.
    [Show full text]